Journal
ONCOLOGY REPORTS
Volume 37, Issue 5, Pages 2897-2904Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/or.2017.5575
Keywords
immunosuppression; lymphatic metastasis; CD11b antigen; Ly6C antigen; mouse; interleukin-6
Categories
Funding
- JSPS KAKENHI [24791982, 26462854, 26861748]
- Grants-in-Aid for Scientific Research [24791982, 26861748, 17K11890, 15K11096, 26463055, 15K11331, 26462854] Funding Source: KAKEN
Ask authors/readers for more resources
Myeloid derived suppressor cells (MDSCs) localize to hematopoietic organs and peripheral blood during inflammation or tumor tissues and lymph nodes in the presence of a tumor. However, whether there are differences in MDSCs found in the primary tumor and metastases is unknown. In the present study, we established a cell line of metastasized tumor cells to a lymph node, L5-11, which were derived from the Sq-1979 mouse buccal mucosa squamous cell carcinoma cell line. We then analyzed tumor immunogenicity, especially with regard to MDSCs, to clarify the differences between the primary tumor and metastases, using an isogenic heterotopic tumor transplantation model. Our data showed that the population of intratumoral MDSCs, especially polymorphonuclear MDSCs in the lymph node metastasis model were significantly increased compared with syngeneic grafts from the primary cell line Sq-1979 after 21 days. Furthermore, we identified that the lymph node metastasis cell line had increased expression of genes that promote the expansion of MDSCs, tumor growth and metastasis. Hence, these data suggest that tumor immunosuppression can occur via activation of MDSCs. However, further examination is required to clarify whether all or a subset of these factors from the lymph node metastasis tumor cells are required to induce intratumoral MDSCs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available